[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stomach-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stomach-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,50,79,107,140,164,190,214,245,273,369,394,413,450,485,510,530,550,571,594,639,670,706,731,753],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100641453","transcriptional-pathways-of-surgical-pain-modulated-by-music-therapy-exposure-transpose-100641453",false,"NCT07653594","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE): A Single Arm Pilot Study","Inclusion Criteria:\n\n* Age 50 to 80\n* Able to speak and understand English\n* Scheduled to undergo a surgery meeting the following criteria: (1) traditional open surgery (not laparoscopic or robotic) via laparotomy (midline or subcostal incisions), (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces\n* Participant reports pain intensity of 4\u002F10 or above to study staff on day 1 post-surgery or any other day post-surgery through discharge\n\nExclusion Criteria:\n\n* Significant visual impairment that has not been corrected\n* Significant hearing impairment that has not been corrected\n* Significant cognitive impairment that would prevent participant from participating in the study","ALL","50 Years","80 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces. The purpose of this study is (1) to evaluate the feasibility of collecting blood samples prior to surgery, post-surgery and pre- music-assisted relaxation and imagery (MARI) intervention, and immediately post-MARI intervention and (2) to identify gene expression changes associated with MARI and explore their relationship with immediate changes in pain intensity. Participants will be in this study for the duration of their hospital admission for surgery.",[28,29,30,31,32,33],"Surgery","Stomach Cancer","Pancreas Cancer","Bile Duct Cancer","Liver Cancer","Peritoneal Cancer",[35,36],"Music therapy","Music-assisted relaxation and imagery","NOT_YET_RECRUITING","2026-06-15",{"date":40,"type":41},"2026-06-17","ACTUAL",{"date":43,"type":22},"2027-01",{"date":45,"type":22},"2027-12",{"name":47,"class":48},"Case Comprehensive Cancer Center","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":49},"100642624","phase-1-a-phase-1-study-of-im-1617-in-participants-with-advanced-cancer-100642624","NCT07578571","A Phase 1 Study of IM-1617 in Participants With Advanced Cancer","A Phase 1 Study of IM-1617 in Participants With Advanced Malignancies","Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n2. Part A: Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:\n\n   * CRC, all subtypes\n   * NSCLC:\n\n     * Non-squamous cell carcinoma subtypes, such as adenocarcinoma\n     * Squamous cell carcinoma subtype\n   * Breast cancer (subtypes based on estrogen\u002Fprogesterone receptor and HER2 testing according to American Society of Clinical Oncology - College of American Pathologists guidelines):\n\n     * Triple-negative breast cancer\n     * HR+, HER2- subtype\n   * Esophageal, esophagogastric junction, and gastric cancer:\n\n     * Adenocarcinoma subtype\n   * Other histologies, if approved by the Medical Monitor, which may include: head and neck squamous cell carcinoma; cervical cancer; bladder cancer; squamous cell carcinoma subtype of esophageal, esophagogastric junction, and gastric cancer; HER2+ breast cancer\n3. Part B Cohorts - Histological diagnosis of one of the following unresectable locally advanced or metastatic solid tumors:\n\n   * Cohort B1: CRC, all subtypes\n   * Cohort B2: NSCLC\n\n     * Non-squamous cell carcinoma subtypes, such as adenocarcinoma\n     * Squamous cell carcinoma subtype\n   * Cohorts B3 and B4: Cohort-specific disease indications may include those listed for Part A\n4. Participants must have disease that is considered to be noncurative and meet the appropriate criteria below:\n\n   * Part A only: Participants have progressed on, were intolerant to, or have a contraindication to prior SOC treatments, with no satisfactory SOC treatment options available.\n   * Part B only:\n\n     * Cohort B1 (CRC):\n\n       * Participants must have previously progressed on, were intolerant to, or have a contraindication to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, bevacizumab, and for those with RAS wild-type tumors, an anti-epidermal growth factor receptor (EGFR)-directed monoclonal antibody in advanced disease setting.\n       * Participants with actionable biomarkers must have been treated with at least one prior appropriate biomarker-directed therapy.\n       * If any of these therapies was given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.\n     * Cohort B2 (NSCLC):\n\n       * Participants must have previously progressed on, were intolerant to, or have a contraindication to platinum-based chemotherapy and a programmed cell death-1 (PD-1)\u002Fprogrammed death ligand 1 (PD-L1) monoclonal antibody (given concurrently or sequentially with chemotherapy) in advanced disease setting.\n       * Participants with actionable biomarkers must have been treated with at least one prior appropriate targeted therapy.\n       * If any of these therapies was given in the adjuvant setting, disease must have progressed within 6 months after completing therapy.\n     * Cohorts B3 and B4: Criteria will be specified based on the disease indications selected.\n5. Participants must have measurable disease as defined per RECIST v1.1\n\nExclusion Criteria:\n\n1. Previously treated with an antibody-drug conjugate (ADC) with a topoisomerase-1 (TOP1) inhibitor payload. Exception: Participants with NSCLC or breast cancer may have received up to one prior ADC with a TOP1 inhibitor payload\n2. History of anaphylactic reaction to TOP1 inhibitors (e.g., irinotecan) or TOP1 inhibiting ADCs\n3. Life expectancy \\\u003C 12 weeks\n4. Prior solid organ transplant\n5. Symptomatic ascites or pleural effusion\n6. Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n7. Known history of another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of recurrence for at least 2 years and approved by the Medical Monitor","18 Years",{"count":59,"type":22},175,[61],"PHASE1","This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).\n\nThis study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.",[64,65,66,67,29,68],"Colorectal Cancer","Non-Small Cell Lung Cancer","Breast Cancer","Esophageal Cancer","Cancer","RECRUITING","2026-06-11",{"date":38,"type":41},{"date":73,"type":41},"2026-05-21",{"date":75,"type":22},"2029-01",{"name":77,"class":78},"Immunome, Inc.","INDUSTRY",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":96,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":49},"100536304","equity-gi-a-prospective-study-to-enhance-quality-inclusivity-and-trial-participation-in-black-patients-with-gastrointestinal-cancer-100536304","NCT06263088","EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.","Inclusion Criteria:\n\n1. Adult ≥ 18 years old.\n2. Newly diagnosed Black GI cancer participants irrespective of stage. Eligible tumor types include anal carcinoma, rectal cancer, colon cancer, small bowel cancer, appendix carcinoma, hepatobiliary cancer, pancreatic cancer, gastroesophageal cancer, gastrointestinal neuroendocrine tumors, and gastrointestinal stromal tumor.\n3. Patient able and willing to comply with study procedures\n4. The patient is able to understand and willing to sign and date the written informed consent form at the screening visit.\n\nExclusion Criteria:\n\n* NONE",{"count":86,"type":22},200,[25],"This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder, liver, neuroendocrine tumor of gastrointestinal origin).\n\nThis study has 3 components as follows-\n\n1. Ensuring appropriate biomarker testing and evidence-based care: Biomarkers are molecules in the tumor or blood that indicate normal or abnormal processes in participant's body and may indicate an underlying condition or disease. Various molecules, such as DNA (genes), proteins, or hormones, can serve as biomarkers since they all indicate something about participant's health. Biomarker testing can also help choose participant's treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to participant's treating physician. Participants will receive standard-of-care treatment if participant enroll in this study. Participant will not receive any experimental treatment.\n2. Assistance with clinical trial enrollment. The study team will help participants enroll in a clinical trial appropriate for participant's condition. However, enrolling in a clinical trial is totally up to the participant.\n3. Health literacy: The study team will provide information relevant to participant's diagnosis to enrich participant's understanding of participant's condition and treatment. Investigator will provide questionnaires to assess participant's understanding before and after participant's have been provided with educational\u002Finformational material appropriate for participant's diagnosis.",[90,91,92,93,67,29,94,30,32,95],"Gastrointestinal Cancer","Colon Cancer","Rectal Cancer","Anal Cancer","Appendix Cancer","Neuroendocrine Tumors",[97,98],"Gastrointestinal cancer","African Americans","2026-05-19",{"date":101,"type":41},"2026-05-22",{"date":103,"type":41},"2024-12-01",{"date":105,"type":22},"2026-09-30",{"name":47,"class":48},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":49},"100567833","phase-1-brodalumab-in-the-treatment-of-immune-related-adverse-events-100567833","NCT06673329","Brodalumab in the Treatment of Immune-Related Adverse Events","Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study","Inclusion Criteria:\n\n* Ability to provide written informed consent by subject or guardian\n* Individuals \\>18 years of age\n* Diagnosis of an irAE clinically suspected to be IL-17 mediated\n* Intent-to-treat or prior treatment with systemic steroids for irAE management\n* Histology-proven primary advanced or metastatic solid organ malignancy treated with immunotherapy. Patients being treated with curative intent are not eligible to enroll.\n* Subject has a negative test for tuberculosis during screening defined as either: negative purified protein derivative (PPD) (\\\u003C 5 mm of induration at 48 to 72 hours after test is placed) OR negative QuantiFERON test. Tuberculosis testing must be performed within 30 days prior to trial initiation.\n* Subjects with a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative QuantiFERON test.\n* Subjects with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or subjects with a positive or indeterminate QuantiFERON test are allowed if they have all of the following: no symptoms of tuberculosis (defined as fever, shortness of breath, cough or night sweats), documented history of a completed course of adequate prophylaxis (per local standard of care), no known exposure to a case of active tuberculosis after most recent prophylaxis, no evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of brodalumab.\n\nExclusion Criteria:\n\n* Estimated creatinine clearance \\\u003C 40 mg\u002Fmin\n* Active suicidal ideation or severe depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders Version IV criteria (DSM-IV)) at the time of enrollment or a PHQ-9 score \\> 20\n* History of prior suicide attempts\n* PHQ-9 score greater \\>5 and \\\u003C 20 without an established mental health provider who verifies stability in their depression\n* Current or prior drug or alcohol abuse within the past 6 months (as defined by the DSM IV)\n* In the opinion of the investigator, the patient requires additional immunosuppressive treatment (other than corticosteroids and brodalumab)\n* Known hypersensitivity or contraindication to brodalumab, corticosteroids or any components of brodalumab\n* Prior treatment with brodalumab\n* Pregnancy, breastfeeding, or use of a nonreliable method of contraception\n\n  * For patients assigned female at birth: lack of willingness to use highly effective methods of birth control during treatment and for at least 4 weeks after the last dose of brodalumab (except if surgically sterile or at least 2 years postmenopausal, with postmenopausal status confirmed by Follicle-Stimulating Hormone (FSH) in the postmenopausal range).\n  * Highly effective methods of birth control include: use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Oral contraceptive pills must be supplemented by a barrier method.\n  * Patients planning to become pregnant while enrolled in the study and within 4 weeks after the last dose of brodalumab will not be permitted to enroll\n* Chronic or current severe infection requiring IV therapy\n* Evidence of active hepatitis B, C, or tuberculosis.\n* History of latent tuberculosis infection which is incompletely treated based upon local standard of care or which was never treated\n* History of or active Crohn's disease.\n* Myocardial infarction, unstable angina pectoris or stroke within the past 12 months prior to the first investigational product dose\n* Any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.\n* Any medical condition or treatment for a condition that, in the opinion of the investigator, might interfere with participation in the study or affect the reliability of clinician assessment or patient self-report\n* Other known clinically significant active medical conditions, such as:\n\n  * Severe cardiovascular disease, including advanced heart failure (American Heart Association Stage D)\n  * Aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal or greater than 3 times the upper limit of normal in patients with liver metastases measured on at least two separate occasions\n  * Direct bilirubin greater than or equal to 1.5 mg\u002FdL in patients with or without liver metastases\n  * Bone marrow insufficiency unrelated to the irAE (according to investigator judgment) with White Blood Cell (WBC) \\\u003C2000\u002Fmm3, absolute neutrophil count \\\u003C1500\u002F mm3, thrombocytopenia (platelet count) \\\u003C50,000\u002Fmm3, hemoglobin \\\u003C 8.0 g\u002FdL\n* Plan to proceed with further curative intent treatment for cancer at the time of enrollment despite the presence of irAE\n* Participation in another therapeutic clinical trial and receipt of investigational drugs within 4 weeks before the screening visit\n* Previous diagnosis of an autoimmune disease or administration of immunosuppressants in a time frame that would impede interpretation of brodalumab administration\n* Planned use of immunosuppressive agents other than steroids (including infliximab, vedolizumab, tocilizumab etc.) or administration of such agents within 28 days of trial initiation\n* Administration of live-virus vaccines within 4 weeks before the first dose of brodalumab",{"count":115,"type":22},11,[61],"The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.",[66,67,119,120,121,122,123,29,124,91,92,125,126,32,127,128,129,130],"Kidney Cancer","Lung Cancer","Thyroid Cancer","Gynecologic Cancer","Pancreatic Cancer","Brain Tumor","Head and Neck Cancer","Oral Cancer","Skin Cancer","Prostate Cancer","Testicular Cancer","Solid Tumor","2026-05-11",{"date":133,"type":41},"2026-05-13",{"date":135,"type":41},"2025-03-11",{"date":137,"type":22},"2027-11",{"name":139,"class":48},"Brian Henick, MD",{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":49},"100453641","phase-1-ca-4948-in-combination-with-folfoxpd-1-inhibitor---trastuzumab-for-untreated-unresectable-gastric-and-esophageal-cancer-100453641","NCT05187182","CA-4948 in Combination With FOLFOX\u002FPD-1 Inhibitor +\u002F- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","Phase I Trial of CA-4948 in Combination With FOLFOX\u002FPD-1 Inhibitor +\u002F- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","Inclusion Criteria:\n\n* Advanced unresectable or metastatic histologically or cytologically confirmed adenocarcinoma or squamous cell carcinoma of the stomach, gastroesophageal junction, or esophagus\n* Measurable or evaluable disease defined by RECIST 1.1.\n* Lesions amenable to research biopsy. This criteria can be waived by the PI after documented discussion with the treating physician.\n* Known HER2 status if histology is adenocarcinoma prior to enrollment; results from local CLIA laboratory is acceptable.\n\n  * For Dose Escalation, patients are required to have documented HER2 negative cancer.\n  * For Dose Expansion, patients will be enrolled to either HER2 positive or negative cohorts at the time of enrollment\n* No prior systemic treatment for unresectable\u002Fadvanced gastric, GEJ, or esophageal cancer.\n\n  * Neoadjuvant or adjuvant systemic therapy is allowed; however, surgical resection and adjuvant chemotherapy should have been \\> 3 months from planned C1D1.\n  * Up to two prior cycles of FOLFOX is allowed.\n  * Definitive chemoradiation is allowed if the last date of chemotherapy or radiation (whichever is more recent) is \\> 3 months from planned C1D1.\n  * Prior palliative radiation therapy, including brain radiation, in the unresectable setting is allowed, but the last treatment date should be \\>10 days from planned C1D1.\n* At least 18 years of age\n* ECOG performance status 0 or 1\n* Adequate bone marrow and organ function as defined below:\n\n  * Absolute neutrophil count ≥ 1.5 K\u002Fcumm\n  * Platelets ≥ 100 K\u002Fcumm\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN or ≤ 3 x IULN in patients with documented Gilbert's syndrome\n  * AST(SGOT)\u002FALT(SGPT) ≤ 2.0 x IULN, unless there are liver metastases in which case AST and ALT ≤ 5.0 x IULN\n  * PT\u002FINR ≤ 1.5 x IULN\n  * aPTT ≤ 1.5 x IULN\n  * Creatinine clearance ≥ 35 mL\u002Fmin by Cockcroft-Gault\n* Creatinine phosphokinase (CPK) elevation at screening \\\u003C Grade 2 (CPK \\\u003C 2.5 x IULN)\n* Patients on a cholesterol lowering statin must be on a stable dose with no dose changes within 3 weeks prior to study start.\n* Expansion Cohort B patients only: LVEF above LLN as assessed by MUGA or ECHO\n* The effects of CA-4948 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 3 months after completion of the study\n* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nExclusion Criteria:\n\n* Current use or anticipated need for alternative, holistic, naturopathic, or botanical formulations used for the purpose of cancer treatment. Use of medical marijuana is permitted.\n* A history of other malignancy with the exception of 1) malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease; 2) or known indolent malignancies that do not require treatment and will likely not alter the course of treatment of metastatic gastric, GEJ, or esophageal cancer.\n* History of allogeneic organ or stem cell transplant\n* Currently receiving any other investigational therapeutic agents. Investigational tracers related to imaging studies are allowed with a 7 day-washout.\n* Currently have an intraluminal GI stent (gastric, esophageal, small bowel, colon). Biliary stents are allowed.\n* History of clinically relevant bleeding from their tumor(s). Includes but is not limited to bleeding tumor requiring RBC transfusion, or bleeding requiring more than one endoscopic intervention.\n* Untreated ulcerating tumor. Patients who are endoscopically treated must be assessed by the study PI or delegate for eligibility.\n* Use of systemic therapeutic anticoagulation, including daily baby aspirin, within 5 half-lives of the anticoagulant prior to C1D1. Patients can receive heparin or alteplase flush in their ports.\n* Use of anti-platelet therapies (i.e. P2Y12 inhibitors (clopidogrel, prasugrel, etc.), within 5 half-lives of the anti-platelet therapy prior to C1D1.\n* Use of NSAIDs within 5 half-lives of the NSAID prior to C1D1.\n* Clinically active CNS metastasis; treated and asymptomatic metastasis allowed at the discretion of the PI. Radiotherapy to the brain must be completed \\> 10 days prior to planned C1D1.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to CA-4948, FOLFOX, nivolumab, trastuzumab or other agents used in the study.\n* Concomitant use of drugs with a known risk of causing prolonged QTc and\u002For Torsades de Pointes or a history of risk factors for Torsades de Pointes.\n* Presence of interstitial lung disease or pneumonitis ≥ G2\n* Administration of a live attenuated vaccine within 30 days prior to enrollment.\n* QTc (Bazett) \\>470ms on screening EKG\n* Gastrointestinal condition which could impair absorption of CA-4948 or inability to ingest CA-4948\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days of study entry.\n* Patients with HIV are eligible unless their CD4+ T-cell counts are \\\u003C 350 cells\u002FmcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended. Recommend exclusion of specific ART agents based on predicted drug-drug interactions (i.e., for sensitive CYP3A4 substrates, concurrent strong CYP3A4 inhibitors (ritonavir and cobicistat) or inducers (efavirenz) should be contraindicated).\n* Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, euthyroid participants with a history of Grave's disease (participants with suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study treatment), psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll after discussing with the PI.\n* Participants with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study treatment except for adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent in the absence of active autoimmune disease. Note: treatment with a short course of steroids (\\\u003C 5 days) up to 7 days prior to initiating study treatment is permitted. Inhaled intranasal, intra-articular, and topical steroid uses are permitted.\n* Patients are unwilling to adhere to the lifestyle guidance in protocol.",{"count":148,"type":22},42,[61],"This is a phase I trial of CA-4948 in combination with FOLFOX\u002FPD-1 inhibitor with or without trastuzumab for unresectable gastric, GEJ, and esophageal cancer. During the Dose Escalation portion of the study, different dose levels of CA-4948 in combination with FOLFOX\u002Fnivolumab will be evaluated by BOIN algorithm.\n\nDose Expansion will include Cohorts A and B. Expansion Cohort A will enroll up to 12 patients with HER2 negative gastric, GEJ, and esophageal cancer at the expansion dose of CA-4948 determined during Dose Escalation and will use the same treatment regimen of FOLFOX\u002Fnivolumab. Expansion Cohort B will investigate CA-4948 at the dose determined during Dose Escalation in combination with FOLFOX\u002Fpembrolizumab and trastuzumab in up to 12 patients with HER2 positive disease; however, the initial 6 patients will be considered safety lead-in to confirm the safety and tolerability of this combination; if determined to be safe, an additional 6 patients will be enrolled for a total of 12 in Cohort B.",[152,67,29,153,154],"Gastric Cancer","Esophagus Cancer","Gastroesophageal Junction Cancer","2026-04-21",{"date":157,"type":41},"2026-04-27",{"date":159,"type":41},"2023-06-02",{"date":161,"type":22},"2029-04-30",{"name":163,"class":48},"Washington University School of Medicine",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":19,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100634475","the-effect-of-stress-ball-on-nausea-anxiety-and-fatigue-in-patients-with-stomach-cancer-100634475","NCT07540169","The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer","The Effect of Stress Balls on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer","Inclusion Criteria:\n\n* Between the ages of 18-80\n* Those who agree to participate in the study\n* Those without motor skill loss\n* Patients diagnosed with stomach cancer\n* Patients with hand-arm orientation skills\n\nExclusion Criteria:\n\n* Patients with loss of motor skills\n* Patients who wish to withdraw from the study",{"count":172,"type":22},52,[25],"In this study, we will observe the effects of the Stress Ball.",[29,176,177],"Chemotherapy-induced Nausea and Vomiting","Fatigue",[179],"Stress Ball","2026-04-16",{"date":182,"type":41},"2026-04-20",{"date":184,"type":41},"2025-10-15",{"date":186,"type":22},"2026-05-24",{"name":188,"class":48},"Yuzuncu Yil University",2,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":197,"sex":17,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":189},"100631721","large-language-models-assist-in-tumor-mdt-100631721","NCT07504367","Large Language Models Assist in Tumor MDT","Evaluating Large Language Models as Decision Support Agents in Pan-Cancer Tumor Boards: A Randomized Controlled Trial","Inclusion Criteria:\n\n* A junior doctor with a practicing physician qualification certificate.\n* Oncologists, surgeons, radiation oncologists, radiologists and pathologists with 3 to 5 years of clinical experience.\n* Age: 25 to 33 years old, gender not limited.\n* During the research period, one can participate for no less than 10 hours.\n* Agree to participate in this research and sign the informed consent form.\n\nExclusion Criteria:\n\n* Have participated in the previous diagnosis and treatment of any one of the 20 cases included in the study.",true,"25 Years","33 Years",{"count":201,"type":22},60,[25],"Multidisciplinary teams (MDTs) represent the gold standard for personalized tumor treatment, but they are limited by medical resources and accessibility Limitation. Although large language models (LLMs) have shown promise in medical reasoning, their multidisciplinary practicality in pan-cancer MDTs has not been fully explored. In the early stage of this project, LLMs with high clinical application efficacy were identified through benchmark tests, and an open-label randomized controlled study (RCT) was conducted based on these LLMs. The research aims to explore whether AI-assisted assistance can enhance the accuracy and writing efficiency of MDT diagnosis and treatment reports. This study intends to prospectively collect the diagnosis and treatment information of 20 patients and MDT diagnosis and treatment information. It is planned to recruit 40 junior doctors. Doctors in the intervention group will use LLM to assist in the writing of MDT reports, while doctors in the control group will use traditional information retrieval methods for the writing of MDT reports. Three clinical experts ultimately used a standardized Likert scale to conduct comprehensive and multidisciplinary scoring of the MDT reports of the intervention group and the control group. This study quantitatively compared the diagnosis and treatment quality and efficiency of the MDT AI-assisted model and the traditional model to verify the application potential of large language models in assisting tumor diagnosis and treatment.",[120,66,64,29,32],"2026-03-25",{"date":207,"type":41},"2026-03-31",{"date":209,"type":41},"2026-01-01",{"date":211,"type":22},"2026-12-31",{"name":213,"class":48},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":197,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":225,"conditions":226,"keywords":233,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":49},"100550437","cancer-loyalty-card-study-2-clocs-2-100550437","NCT06447064","Cancer Loyalty Card Study 2 (CLOCS-2)","Cancer Loyalty Card Study 2: a Retrospective Observational Case-Control Study","(CLOCS-2)","Inclusion Criteria (ALL):\n\n* Individuals aged \\>18 years of age\n* Individuals must be residing in the United Kingdom at the time of giving informed consent\n* Individuals must be registered with an NHS GP Practice\n* Individuals must meet the criteria of ONE of the groups. For example, to be eligible for Group 1 (Cases), individuals must have been diagnosed with one of the following cancer types in the last 24 months: Bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine, or vulval; whereas for Group 2 (Controls), individuals must not have received a cancer diagnosis of any type in the last 6 years (except where the diagnosis was of non-melanoma skin cancer).\n* Individuals must be a primary registered cardholder\\* of one of the loyalty cards listed below, and consent to share their loyalty card data with the study team\n* Tesco Clubcard\n* Boots Advantage Card\n* Provision of written informed consent\n* Willing and able to comply with all required study activities\n\n  * The primary registered card holder, i.e., the person who is named on the loyalty card account, must also enrol into the study, if someone other than the registered primary card holder from the same household, wants to take part in the study.\n\nExclusion Criteria (ALL):\n\n* Individuals under the age of 18 years\n* Non-UK residents, at the time of giving informed consent\n* Individuals without an eligible loyalty card, or who have no one in their household who has an eligible loyalty card\n* Individuals who are not the primary registered cardholder in their household and where the primary registered loyalty card holder is not willing to join the study, and\u002For where the primary registered cardholder does not make purchases for or on behalf of the individual\n\nExclusion Criteria (CASES):\n\n• Individuals will not be able to join as a case if:\n\n* they have been diagnosed with an eligible cancer type more than 24 months ago (except where the diagnosis was non-melanoma skin cancer).\n* they have received an ineligible cancer diagnosis within the last 6 years except where the diagnosis was non-melanoma skin cancer).\n\nExclusion Criteria (Controls):\n\n• Individuals will not be able to join as a control (Group 2) if:\n\no they have received any cancer diagnosis in the last six years (except where the diagnosis was non-melanoma skin cancer).",{"count":223,"type":22},2900,"OBSERVATIONAL","Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of symptoms to the start of treatment. Diagnosing cancer when it is still at an early stage, before it has spread, gives surgery, radiotherapy and other treatments the best chance of working.\n\nTherefore, early diagnosis is the most important way to improve cancer outcomes.Most of the cancers usually presents with vague and non-alarming symptoms. Most individuals are diagnosed late when the cancer has already spread, and the prognosis is poor. There are over 200 different types of cancer that can cause many different signs and symptoms. Sometimes symptoms affect specific body areas, such as abdomen or skin. But signs can also be more general, and include weight loss, tiredness (fatigue) or unexplained pain. The type of symptoms varies from person to person.\n\nThe major reasons for not presenting to the GP with symptoms such as these are \"not wanting to waste the GP's time\" and normalisation of these symptoms.\n\nThe persistence of a symptom, social influence and awareness encourage help-seeking behaviours in primary care. However, few believe their symptom(s) might be a sign of cancer. Consequently, people might choose to self-manage their symptoms by using over-the-counter medication, and to seek advice from other sources, (pharmacists, family, internet), rather than a primary care physician.\n\nRATIONALE FOR CURRENT STUDY\n\nAn early cancer diagnosis is essential for receiving treatment as early as possible to have the best chance for successful treatment. Early diagnosis of cancer can be challenging. Sometimes, the cancer symptoms resemble common illnesses and could resolve with the use of over-the-counter medications and other remedies until they become persistent or debilitating. The present study focuses on ten cancer forms: colon, oesophageal, stomach, liver, bladder, uterine, vulval, ovarian, endometrial and pancreatic. Patients diagnosed with the cancers mentioned above often report experiencing vague symptoms (such as abdominal or back pain, indigestion, feeling full etc). They often use over-the-counter medication to manage their symptoms before seeing a doctor.\n\nInformation about how often and what products participants purchase (e.g. pain killers, digestive products and natural remedies) to care for these symptoms could help identify these cancers a few crucial weeks or months earlier and encourage people to seek help sooner from their doctors.",[123,91,227,29,32,228,229,230,231,232],"Oesophageal Cancer","Bladder Cancer","Uterine Cancer","Vulvar Cancer","Ovarian Cancer","Endometrial Cancer",[231,234,235,236],"Epidemiology","Observational Study","Risk Assessment","2026-03-24",{"date":205,"type":41},{"date":240,"type":41},"2026-02-04",{"date":242,"type":22},"2027-04",{"name":244,"class":48},"Imperial College London",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":189},"100598359","phase-2-ivonescimab-in-comb-with-folfox-in-advanced-her2-neg-gea-100598359","NCT07070466","Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA","A Single-Arm, Phase II Study of Ivonescimab in Combination With FOLFOX in Advanced HER2 Negative Gastroesophageal Adenocarcinomas","Inclusion Criteria:\n\n* Patients must have a pathologically confirmed diagnosis of adenocarcinoma of the esophagus, gastroesophageal junction, stomach. Squamous cell tumors are excluded. Patients with locally tested HER2 positive tumors (HER2+) tumors are excluded.\n* Participants must have disease that can be evaluated radiographically. This includes disease that may be measurable or non-measurable as per RECIST version 1.1.\n* Patients may not have received prior therapy for Stage IV disease. Patients may have received prior adjuvant therapy if more than 6 months have elapsed between the end of adjuvant therapy and registration.\n* Age ≥18 years old. Because there is no dosing or adverse event data for ivonescimab with FOLFOX in participants \\\u003C18 years of age, children are excluded from this study.\n* ECOG Performance status of 0-2\n* Participants must meet the following organ and marrow function as defined below:\n\n  1. absolute neutrophil count ≥1,500\u002FmcL\n  2. hemoglobin \\> 9.0 g\u002FdL\n  3. platelets ≥100,000\u002FmcL\n  4. total bilirubin ≤ 1.5x institutional upper limit of normal (ULN). For patients with liver metastases or confirmed\u002Fsuspected Gilbert syndrome, TBIL ≤3 × ULN\n  5. AST(SGOT)\u002FALT(SGPT) ≤2.5 × institutional ULN. For patients with liver metastases, AST and ALT ≤ 5 × ULN\n  6. Creatinine ≤ institutional ULN OR glomerular filtration rate (GFR) ≥50 mL\u002Fmin.\n  7. Urine protein \\\u003C 2+ or 24-hour protein quantification \\\u003C 1.0 grams.\n  8. Coagulation: prothrombin time (PT) or international normalized ratio (INR) ≤ 1.5 × ULN, and partial prothrombin time (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless abnormalities are unrelated to coagulopathy) This applies only to patients who are not on therapeutic anti-coagulation. Patients receiving therapeutic anti-coagulation should be on a stable dose.\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Participants with brain metastases (active brain metastases) or leptomeningeal disease are not eligible. Patients with treated brain metastases who are off systemic steroids \\> 2 weeks and have documented radiographic stability over 4 weeks since initial brain metastasis diagnosis may be considered in discussion with the overall principal investigator.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* The effects of ivonescimab on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Contraception should continue for 9 months from the last dose of any study medication.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 9 months after completion of ivonescimab administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior treatment with a PD-1 or PD-L1 inhibitor is exclusionary unless this therapy was completed \\> 6 months prior to the time of enrollment as part of adjuvant therapy.\n* Major surgical procedures or serious trauma within 4 weeks prior to enrolment, or plans for major surgical procedures within 4 weeks after the first dose (as determined by the investigator). Minor local procedures (excluding central venous catheterization and port implantation) within 3 days prior to randomization.\n* Participants who have not recovered from adverse events due to prior adjuvant anti-cancer therapy except for alopecia or peripheral neuropathy grade 1 or less.\n* Participants who are receiving any other investigational agents for this condition are not eligible.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ivonescimab. Patients with prior oxaliplatin and\u002For 5FU allergic reactions during adjuvant therapy are allowed if they have undergone prior desensitization with allergy and documented tolerance at standard dosing after desensitization.\n* Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated with ivonescimab. These potential risks may also apply to other agents used in this study.\n* History of perforation of the gastrointestinal tract and\u002For fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to randomization.\n* Clinically significant hypertension with systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy.\n* History of any grade arterial thromboembolic event, venous thromboembolic event of Grade 3 and above as specified in National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 12 months prior to randomization.\n* Participants with a documented history of impaired wound healing are excluded.\n* Participants with a history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Participants with uncontrolled intercurrent illness that would interfere with ability to participate in the opinion of the treating investigator.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Unstable angina, myocardial infarction, congestive heart failure (New York Heart Association \\[NYHA\\] classification ≥ grade 2) or unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 12 months prior to randomization, or other cardiac impairment that may affect the safety evaluation of the study drug (eg, poorly controlled arrhythmias, myocardial ischemia).\n* Subjects with any condition requiring systemic treatment with either corticosteroids (\\>2mg daily dexamethasone equivalent) or other immunosuppressive medications within 14 days of treatment. Premedication for hypersensitivity reactions (e.g. to contrast for CT or gadolinium for MRI) is allowed.\n* Active systemic infection requiring intravenous antibiotics or intravenous monoclonal antibody treatments within 7 days of cycle 1 day 1.\n* Participants with a known history of Human Immunodeficiency Virus (HIV) infection are excluded unless they meet all of the following criteria:\n\n  * Stable antiretroviral therapy (ART) for at least 12 weeks prior to enrollment\n  * No history of AIDS-defining conditions.\n  * CD4+ T-cell count ≥ 350 cells\u002Fmm³ at screening\n  * HIV viral load ≤ 50 copies\u002FmL at screening.\n  * No significant comorbidities associated with HIV infection that could interfere with the safety or efficacy of the investigational treatment.\n  * No concurrent use of prohibited medications that may interfere with the study drug or cancer therapy\n* History of bleeding tendencies or coagulopathy and\u002For clinically significant bleeding symptoms or risk within 4 weeks prior to randomization, including but not limited to:\n\n  * Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots). Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed.\n  * Nasal bleeding \u002Fepistaxis (bloody nasal discharge is allowed)\n  * Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable prior to randomization is not allowed. The use of full-dose anticoagulants is permitted as long as the international normalized ratio (INR) or activated partial thromboplastin time (aPTT) is within therapeutic limits according to the medical standard of the enrolling institution.\n* History of non-infectious pneumonitis requiring therapy within 4 weeks of registration.",{"count":253,"type":22},40,[255],"PHASE2","This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.",[258,153,29],"Stomach Cancer Stage IV",[260,261,262,263],"stomach cancer","esophageal cancer","Phase 2","Immunotherapy","2026-03-04",{"date":266,"type":41},"2026-03-06",{"date":268,"type":41},"2025-10-10",{"date":270,"type":22},"2028-09-01",{"name":272,"class":48},"Massachusetts General Hospital",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":280,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":354,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":49},"100432171","virtual-reality-for-gi-cancer-pain-to-improve-patient-reported-outcomes-100432171","NCT04907643","Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","Inclusion Criteria:\n\n* Have a primary malignancy of the biliary tract, colon, liver, pancreas, peritoneum, rectum, small intestine, or stomach, with no plan for resection during the study period\n* Tumor types including, but not limited to, adenocarcinoma, squamous cell carcinoma, neuroendocrine tumors, and tumors of mesenchymal origin will be eligible\n* Have clinically significant visceral pain, measured using the standardized NIH PROMIS GI Pain Scale defined as scoring at least 5 points above the nationally normed score\n* Ability to read and write in English\n\nExclusion Criteria:\n\n* Have a condition that interferes with VR usage, including but not limited to seizures, facial injury precluding safe placement of headset, and visual impairments\n* Have cognitive impairment that affects protocol participation. This will be done with a three part cognitive assessment during the initial phone call to assess eligibility followed by consent discussion if eligible.\n* Have brain metastases\n* Have a prognosis of \\\u003C3 months from the time of enrollment per treating oncologist","99 Years",{"count":282,"type":22},360,[25],"Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain.\n\nTo address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.",[286,287,288,289,290,30,32,91,291,29,292,33,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,258,312,313,314,93,315,316,317,318,319,320,94,321,31,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,153,339,340,341,342,343,344,345,346,347,92,348,349,350,351,352,353],"Cancer Pain","Visceral Pain","Gastrointestinal Neoplasms","Cancer of Gastrointestinal Tract","Small Intestine Cancer","Biliary Tract Cancer","Rectum Cancer","Gastrointestinal Cancer Metastatic","Gastrointestinal Cancers - Anus","Gastrointestinal Cancers - Stomach","Gastrointestinal Cancers - Colorectal","Gastrointestinal Cancers - Small Intestine","Small Intestine Cancer Stage III","Small Intestine Cancer Stage IV","Small Intestine Cancer, Recurrent","Pancreas Cancer, Stage III","Pancreas Cancer, Stage IV","Pancreas Cancer, Metastatic","Pancreas Cancer, Recurrent","Liver Cancer Stage IIIa","Liver Cancer Stage IIIb","Liver Cancer Stage IIIc","Liver Cancer Stage IV","Colon Cancer Stage III","Colon Cancer Stage IV","Stomach Cancer Stage III","Stomach Cancer Recurrent","Rectum Cancer, Recurrent","Gastrointestinal Cancers - Liver","Anal Cancer Stage III","Anal Cancer Stage IV","Anal Cancer Recurrent","Anal Cancer Metastatic","Anal Cancer, Stage IIIA","Anal Cancer, Stage IIIB","Ampullary Cancer","Bile Duct Cancer Stage III","Bile Duct Cancer Stage IV","Bile Duct Cancer Stage IVA","Bile Duct Cancer Stage IVB","Bile Duct Cancer Recurrent","Carcinoid Tumor","Carcinoid Tumor of Pancreas","Carcinoid Tumor of Large Intestine","Carcinoid Tumor of GI System","Carcinoid Tumor of Colon","Carcinoid Tumor of Liver","Carcinoid Tumor of Cecum","Carcinoid Tumor of Ileum","Carcinoid Tumor of Rectum","Carcinoid Tumor of the Small Bowel","Carcinoid Tumor of the Stomach","Large Intestine Cancer","Esophagus Cancer, Stage III","Esophagus Cancer, Stage IV","Esophagus Cancer, Recurrent","Gallbladder Cancer","Gallbladder Cancer Stage III","Gallbladder Cancer Stage IV","Gastric (Stomach) Cancer","Neuroendocrine Tumor","Peritoneum Cancer","Esophagus Cancer, Stage I","Esophagus Cancer, Stage II","Gallbladder Cancer Stage I","Gallbladder Cancer Stage II","Bile Duct Cancer Stage I","Bile Duct Cancer Stage II",[355,356,357,358,359],"Virtual Reality","VR","support","GI cancer","cancer pain","2026-02-18",{"date":362,"type":41},"2026-02-20",{"date":364,"type":41},"2021-10-05",{"date":366,"type":22},"2027-03-16",{"name":368,"class":48},"Cedars-Sinai Medical Center",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":49},"100579188","phase-1-study-of-cea-targeting-car-t-ptc13-in-the-treatment-of-cea-positive-advanced-malignant-solid-tumors-100579188","NCT06821048","Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors","A Phase I Clinical Study of Anti-CEA CAR-T (PTC13) Therapy in the Treatment of CEA-positive Advanced Malignant Solid Tumors","Inclusion Criteria:\n\nSubjects must meet all the following criteria to be eligible for the study:\n\n1. Age≥18 years, regardless of gender.\n2. Diagnosed with advanced, metastatic, or recurrent malignant tumors confirmed by histology or pathology, primarily including colorectal cancer, esophageal cancer, gastric cancer, pancreatic cancer, lung cancer, or cholangiocarcinoma.\n3. Failure of at least second-line standard therapy (due to disease progression or intolerance, such as surgery, chemotherapy, radiotherapy, etc.) or a lack of effective treatment options.\n4. Immunohistochemical staining of tumor samples within 3 months confirming CEA positivity (distinct membrane staining with a positivity rate of≥10%); if the immunohistochemical result of the tumor sample is more than 3 months old at the time of screening (distinct membrane staining with a positivity rate of≥10%), the patient's serum CEA must exceed 10µg\u002FL.\n5. At least one evaluable lesion according to RECIST 1.1 criteria.\n6. ECOG score of 0-2 (Appendix 2).\n7. No severe psychiatric disorders.\n8. Unless specifically stated otherwise, subjects' major organ functions must meet the following conditions:\n\n   1. Blood routine: WBC\\>2.0×109\u002FL, neutrophils\\>0.8×109\u002FL, lymphocytes\\>0.5×109\u002FL, platelets\\>50×109\u002FL, hemoglobin\\>90g\u002FL;\n   2. Cardiac function: Echocardiography indicating a left ventricular ejection fraction≥50%, and no significant abnormalities on electrocardiogram;\n   3. Renal function: Serum creatinine≤2.0×ULN;\n   4. Liver function: ALT and AST ≤3.0×ULN (may be relaxed to≤5.0×ULN if liver tumor infiltration is present);\n   5. Total bilirubin≤2.0×ULN;\n   6. Oxygen saturation\\>92% without supplemental oxygen. 9. Eligible for apheresis or venous blood collection, with no contraindications for cell collection.\n\n      10\\. Subjects agree to use reliable and effective contraceptive methods from signing the informed consent form until 1 year after receiving CAR-T cell infusion (excluding natural family planning methods).\n\n      11\\. The patient or their guardian agree to participate in this clinical trial and signs the ICF, indicating an understanding of the trial's purpose and procedures and willingness to participate.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will be excluded from the study:\n\n1. Clinically symptomatic central nervous system or leptomeningeal metastasis at the time of screening, or other evidence suggesting that central nervous system or leptomeningeal metastases are not controlled, as judged unsuitable for inclusion by the investigator.\n2. Participation in another clinical study within 1 month prior to screening.\n3. Receipt of live attenuated vaccines within 4 weeks prior to screening.\n4. Receipt of the following anti-tumor treatments before screening: Chemotherapy, targeted therapy, or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter).\n5. Presence of active or uncontrolled infections requiring systemic treatment.\n6. Patients with intestinal obstruction, active gastrointestinal bleeding, a history of major gastrointestinal bleeding within 3 months, severe gastroduodenal ulcers, or severe gastrointestinal inflammation such as ulcerative colitis.\n7. Toxicity from previous anti-tumor therapy that has not improved to baseline levels or≤Grade 1, except for alopecia or peripheral neuropathy.\n8. Presence of any of the following cardiac conditions:\n\n   1. New York Heart Association (NYHA) Stage III or IV congestive heart failure;\n   2. Myocardial infarction or coronary artery bypass graft (CABG) within 6 months prior to enrollment;\n   3. Clinically significant ventricular arrhythmia or history of unexplained syncope (excluding vasovagal or dehydration-related causes);\n   4. History of severe non-ischemic cardiomyopathy.\n9. Presence of active autoimmune diseases or other conditions requiring long-term immunosuppressive therapy.\n10. Diagnosis of another untreated malignancy within the past 3 years, except for in situ cervical cancer or basal cell carcinoma of the skin.\n11. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood hepatitis B virus (HBV) DNA levels exceeding the normal range; positive for hepatitis C virus (HCV) antibodies with peripheral blood HCV RNA levels exceeding the normal range; positive for human immunodeficiency virus (HIV) antibodies; or positive syphilis test.\n12. Pregnant or breastfeeding women.\n13. Any other conditions deemed unsuitable for participation in the study by the investigator.",{"count":377,"type":22},18,[61],"This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of FAST CAR-T (PTC13) and phase II Recommended dose.",[64,29,123,381],"Metastatic Cancer",[383,384],"FAST CAR-T","CEA-positive advanced malignant solid tumors","2026-01-21",{"date":387,"type":41},"2026-01-23",{"date":389,"type":41},"2024-07-24",{"date":391,"type":22},"2027-12-01",{"name":393,"class":48},"Weijia Fang, MD",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":23,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":411,"locationsCount":49},"100620214","phase-1-a-first-in-human-study-of-3h-10000-in-patients-with-unresectable-or-metastatic-solid-tumors-100620214","NCT07354711","A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","A Phase I\u002FII Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors","Inclusion Criteria:\n\n* Subjects must be willing and able to sign the ICF and to adhere to the study visit schedule and other protocol requirements.\n* Male or female subjects aged ≥18 years at the time of signing the ICF.\n* According to RECIST v1.1, there is at least one measurable lesion.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 point.\n* Life expectancy of ≥3 months.\n\nExclusion Criteria:\n\n* Meningeal diseases or carcinomatous meningitis.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage every two weeks or more frequently.\n* Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.\n* Any AEs induced by prior anti-tumor therapy having not resolved to Grade 1 or lower (except for alopecia or any other Grade 2 AEs assessed by the investigator as not being associated with any safety risk).\n* Any corneal or retinal disease\u002Fkeratopathy assessed by the investigator as of clinical significance, including but not limited to bullous\u002Fband keratopathy, corneal abrasion, inflammation\u002Fulceration, and keratoconjunctivitis.",{"count":402,"type":22},170,[61,255],"The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .",[120,29],"2026-01-18",{"date":385,"type":41},{"date":409,"type":41},"2026-01-04",{"date":75,"type":22},{"name":412,"class":78},"3H Pharmaceuticals Co., Ltd.",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":197,"sex":17,"minAge":421,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":424,"conditions":425,"keywords":434,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":449},"100467447","cfdna-assay-prospective-observational-validation-for-early-cancer-detection-and-minimal-residual-disease-100467447","NCT05366881","cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease","cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse","CAMPERR","Case Inclusion Criteria:\n\n* Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagnosed \\>5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid; Leukemia, Lymphoma, Multiple Myeloma\n* Able and willing to provide informed consent\n* ≥40 years of age\n\nCase Exclusion Criteria:\n\n* Currently receiving any treatment for cancer\n* Currently taking any demethylating agents\u002FDNA hypomethylating agents\n* Simultaneously diagnosed with two or more invasive cancers\n* Diagnosed with any invasive or non-invasive cancer in addition to the index cancer in the last 5 years\n* Currently diagnosed with any chronic hematopoietic cancer (e.g. chronic CLL) in addition to the index cancer\n* Currently diagnosed with any myelodysplastic syndromes and\u002For precursor hematologic conditions (e.g. MGUS) in addition to the index cancer\n* Women who are known to be pregnant (self-reported)\n\nControl Inclusion Criteria\n\n* Not diagnosed with any cancer in the last 5 years (non-invasive cancer is allowed)\n* Able and willing to provide informed consent\n* ≥40 years of age\n\nControl Exclusion Criteria\n\n* Currently receiving any treatment for cancer\n* Currently taking any demethylating agents\u002FDNA hypomethylating agents\n* Women who are known to be pregnant (self-reported)","40 Years",{"count":423,"type":22},7000,"This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care.\n\nAdditionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.",[426,66,228,427,64,232,67,29,125,428,429,120,430,431,231,123,128,432,433,121],"Brain Cancer","Cervical Cancer","Hepatobiliary Cancer","Leukemia","Lymphoma","Multiple Myeloma","Renal Cancer","Sarcoma",[435,436,437,438,439],"Multi-cancer early detection","Liquid Biopsy","Methylome","Cancer screening","cell-free DNA","2026-01-16",{"date":442,"type":41},"2026-01-20",{"date":444,"type":41},"2022-05-03",{"date":446,"type":22},"2027-03",{"name":448,"class":78},"Adela, Inc",17,{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":470,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":49},"100571099","target-specific-immunopet-imaging-of-digestive-system-carcinoma-100571099","NCT06715839","Target-specific immunoPET Imaging of Digestive System Carcinoma","Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma","Inclusion Criteria:\n\n1. Aged 18-75 years old and of either sex；\n2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","75 Years",{"count":459,"type":22},400,[25],"The aim of this study is to establish and optimize the target-specific PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.",[463,464,465,466,467,32,29,91,292,123,153,468,290,94,469],"Malignancy","Digestive Cancer","Digestive System Neoplasm","Digestive System Carcinoma","Digestive System Cancer","Gallbladder Carcinoma","Bile Duct Carcinoma",[471,472,473,474,475],"human epidermal growth factor receptor 2 (HER2)","Trophoblast cell surface antigen 2 (TROP2)","Glypican-3 (GPC3)","Glycoprotein A33 (gpA33)","Nectin cell adhesion molecule-4 (Nectin-4)","2025-12-25",{"date":478,"type":41},"2025-12-31",{"date":480,"type":41},"2024-12-04",{"date":482,"type":22},"2027-09",{"name":484,"class":48},"RenJi Hospital",{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":496,"conditions":497,"keywords":500,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":49},"100617789","evaluation-of-the-neomom-gastric-video-capsule-for-gastric-cancer-screening-100617789","NCT07323186","Evaluation of the NEOmom® Gastric Video Capsule for Gastric Cancer Screening","NEOTOGAS","Inclusion Criteria:\n\n* Male or female patient,\n* Aged between 50 and 74 inclusive with a life expectancy of at least 10 years,\n* Undergoing screening or surveillance colonoscopy (for colorectal cancer or polyps)\n* Patient who has received verbal and written information as well as a patient booklet on the VCE-CM examination and has given their written informed consent.\n* Patient affiliated with a social security scheme\n* Effective contraception throughout the study for women of childbearing age\n\nExclusion Criteria:\n\n* Patients who have had or currently have the following (items from the TOGAS pilot study\u002Fspecific to endoscope use) will not be included in the study:\n* An EOGD in a high-volume endoscopy centre within the last 3 years\n* Known gastric cancer\n* Known genetic cancer syndromes\n* Previous gastrectomy or bariatric gastric surgery\n* Known gastric precancerous condition (gastric atrophy, intestinal metaplasia, dysplasia)\n* Acute gastrointestinal haemorrhage in the last 4 weeks\n* A coagulation disorder or medication that prevents biopsy sampling\n* A risk associated with sedation or anaesthesia\n* Severe heart disease\n* An inability to actively consent to participation in the study, and patients under guardianship or legal protection.\n\nPregnant or breastfeeding patients will not be included.\n\nPatients with the following conditions (specific to VCE-CM examination) will not be included in the study:\n\n* Swallowing disorders or known gastroparesis\n* A history of digestive surgery\n* Clinical or radiological signs suggestive of narrowing of the digestive tract\n* An occlusive or sub-occlusive condition, a known or suspected history of stenosis or digestive fistula\n* Left heart failure with orthopnoea\n* Overweight (\\> 135 kg)\n* Reduced mobility (i.e. unable to transfer or move themselves)\n* Persons with pacemakers, defibrillators or metallic foreign bodies (with the exception of dental implants) will not be included in order to avoid interference with the robot.","74 Years",{"count":494,"type":22},100,[25],"Gastric cancer remains a major public health concern, with approximately 6,600 new cases diagnosed each year in France. Despite therapeutic progress, its overall prognosis is still poor: the 5-year survival rate across all stages remains below 30%. This survival is closely linked to the stage at diagnosis. Early-stage gastric cancer has an excellent prognosis, with survival rates above 90%, while advanced-stage disease shows survival below 10%. This dramatic contrast underscores the critical need to develop and implement approaches that enable earlier and more reliable diagnosis. Early detection is therefore one of the most powerful strategies to reduce mortality from this severe and often silent disease.\n\nWithin this context, the overall ambition of the NEOTOGAS project is to contribute to lowering gastric-cancer mortality by improving the ability to diagnose the disease at an early, more treatable stage. The project positions itself within the broader field of prevention, targeting one of the leading and most challenging public health issues. Gastric cancer is often a potentially fatal condition that typically develops over many years, most commonly as a consequence of chronic infection with Helicobacter pylori (H. pylori). Identifying precancerous gastric lesions before the appearance of invasive cancer thus represents a strategic priority for the healthcare system.\n\nOur central hypothesis is that a non-invasive, robot-assisted endoscopic approach using a magnetic-guided capsule-the NEOMOM system-will prove effective for detecting precancerous gastric lesions. If validated, this technology could form the foundation of an organized, large-scale screening program. Such a screening strategy would represent a major innovation, particularly in populations at higher risk due to H. pylori infection or other predispositions. The ability to offer a less invasive, more accessible examination could significantly increase screening adherence and facilitate earlier diagnosis.\n\nThe NEOTOGAS study is based on an innovative combination of technologies: a magnetic-guided videocapsule steered inside the stomach using the NEOMOM robot, supported by artificial intelligence to assist image acquisition and interpretation. The study aims to assess the level of concordance between lesion detection through the current gold-standard procedure (conventional endoscopy) and this new capsule-based examination. Beyond diagnostic performance, the project also integrates several essential dimensions for future implementation: patient acceptability of the procedure, overall cost, duration of the examination, and the potential clinical and organizational benefits of this alternative approach.\n\nA key component of the project is the creation of high-quality image banks. These will support the development of advanced AI models capable of enhancing lesion detection and ensuring the completeness of the stomach examination. Such resources will be instrumental in evaluating whether magnetic-guided capsule endoscopy could realistically be integrated into structured gastric cancer screening pathways in the future. The project therefore aims not only to evaluate a device, but also to explore its broader screening potential and its capacity to transform clinical practice.\n\nThe primary objective of the NEOTOGAS study is to rigorously assess the performance of this innovative medical device, which combines magnetic navigation with AI-assisted image interpretation, in detecting gastric lesions. The AI module plays a dual role: ensuring that the entire stomach is adequately explored and helping highlight images of interest for clinicians during analysis. By improving both completeness and accuracy, the technology could represent a significant advancement over existing non-invasive diagnostic tools.\n\nTo achieve these goals, the study plans to include a total of 100 patients over a 6-month period. This sample size will allow a robust comparison of diagnostic concordance while providing sufficient data to evaluate feasibility, patient experience, and operational parameters. The findings of NEOTOGAS will determine whether magnetic-guided capsule endoscopy can be considered a relevant and effective method for future organized gastric cancer screening programs.",[29,498,499],"Diagnosis","Endoscopy of Stomach (Procedure)",[260],"2025-12-23",{"date":503,"type":41},"2026-01-07",{"date":505,"type":22},"2025-12-15",{"date":507,"type":22},"2026-06-07",{"name":509,"class":48},"Nantes University Hospital",{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":49},"100136578","clinical--pathological-studies-of-upper-gastrointestinal-carcinoma-100136578","NCT01048281","Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma","Inclusion Criteria:\n\n1. Over 18\n2. Diagnosed with gastric or esophageal cancer OR at an increased hereditary risk for upper GI cancer\n\nExclusion Criteria:\n\n1. Under 18\n2. No family or personal history of gastric or esophageal cancer",{"count":494,"type":22},"Our research of the biology of upper gastrointestinal cancers involves the study of tissue samples and cells from biopsies of persons with gastric or esophageal cancer or blood samples from upper gastrointestinal cancer patients and persons at high inherited risk for these cancers. We hope to learn the role genes and proteins play in the development of gastric and esophageal cancer.",[29,519,345,67,520],"Gastro-Esophageal(GE) Junction Cancer","Gastrointestinal Stromal Tumor (GIST)","2025-12-17",{"date":523,"type":41},"2025-12-18",{"date":525,"type":4},"2002-08",{"date":527,"type":22},"2099-01",{"name":529,"class":48},"Stanford University",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":457,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":539,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":546,"leadSponsor":548,"locationsCount":189},"100616844","robotic-gastrectomy-with-5th-arm-100616844","NCT07310888","Robotic Gastrectomy With 5th Arm","Robotic Gastrectomy With a Novel 5th Arm - an International Multicenter Pilot Study","Inclusion Criteria:\n\n* Age 18-75\n* Body mass index \\\u003C35 kg\u002Fm2\n* Newly diagnosed tumors of the stomach \u002F gastro-esophageal junction, scheduled to undergo elective gastrectomy (Proximal gastrectomy, distal gastrectomy, total gastrectomy)\n* Willingness to participate as demonstrated by giving informed consent\n\nExclusion Criteria:\n\n* Previous abdominal surgery precluding performance of MIS gastrectomy\n* Contraindication to general anesthesia\n* Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention\n* Untreated active infection\n* Noncorrectable coagulopathy\n* Presence of another malignancy or distant metastasis\n* Emergency surgery\n* Vulnerable population (e.g., mentally disabled, pregnancy)",{"count":538,"type":22},10,[25],"This is a multicenter single arm clinical pilot study to investigate the safety and feasibility of a novel multiport Sentire Robotic Surgical System with Patient Side Single Arm (5th arm) in patients with gastric cancer undergoing robotic radical gastrectomy. 10 adult patients with newly diagnosed cancer of the stomach deemed operable would be recruited from Prince of Wales Hospital, Hong Kong and Fujita Health University Hospital, Nagoya, Japan.\n\nThe primary aim of this study is to determine the feasibility of robotic surgical procedures performed using the Cornerstone Robotics Sentire Surgical System C1000 Ultra, as measured by the technical success rate of surgery, and to evaluate the safety of the procedures as measured by the incidence of perioperative complications.",[29],"2025-12-16",{"date":544,"type":41},"2025-12-30",{"date":478,"type":22},{"date":547,"type":22},"2028-01-31",{"name":549,"class":48},"Chinese University of Hong Kong",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":559,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":49},"100553525","phase-2-avutometinib-and-defactinib-in-diffuse-gastric-cancer-100553525","NCT06487221","Avutometinib and Defactinib in Diffuse Gastric Cancer","A Phase II Trial of Avutometinib in Combination With Defactinib in Metastatic Diffuse Gastric Cancer","Inclusion Criteria:\n\n1. Histologic or cytologic evidence of gastric\u002Fgastroesophageal junction carcinoma, classified as diffuse type, poorly cohesive, signet ring cell, or mixed type. Patients with known pathogenic CDH1 and\u002For RHOA mutations will be allowed regardless of histology.\n2. Prior therapy with at least one line of therapy for unresectable\u002Fmetastatic disease, which must include platinum and fluoropyrimidine.\n3. ECOG performance status of 0 or 1\n4. Age ≥ 18 years\n5. Adequate organ function, defined by the following laboratory parameters:\n\n   a. Adequate hematologic function, including hemoglobin \\[Hb\\] ≥ 9.0 g\u002FdL; platelets ≥ 100,000\u002Fmm3; and absolute neutrophil count \\[ANC\\] ≥ 1500\u002Fmm3. If a red blood cell transfusion or erythropoiesis-stimulating agent has been administered the Hb must remain stable and ≥ 9 g\u002FdL for at least 1 week prior to first dose of study intervention.\n\n   (i) Subjects with Hgb ≥ 8.5 g\u002FdL and \\\u003C9.0 g\u002FdL are eligible if there is no history of significant cardiovascular risk features as per the investigator (i.e., prior myocardial infarction) b. Adequate hepatic function: (i) total bilirubin ≤ 1.5 × upper limit of normal \\[ULN\\] for the institution; patients with Gilbert syndrome may enroll if total bilirubin is \\\u003C 3.0 mg\u002FdL (51 μmol\u002FL); (ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\n\n   ≤ 2.5 × ULN (or \\\u003C 5 x ULN in patients with liver metastases). c. Adequate renal function with creatinine clearance rate of ≥ 50 mL\u002Fmin, as calculated by the Cockcroft-Gault formula d. International normalized ratio (INR) ≤ 1.5 and partial thromboplastin time (PTT) ≤ 1.5 x ULN in the absence of anticoagulation or therapeutic levels in the presence of anticoagulation.\n\n   e. Albumin ≥ 3.0 g\u002FdL (451 μmol\u002FL). f. Creatine phosphokinase (CPK) ≤ 2.5 x ULN. g. Adequate cardiac function with left ventricular ejection fraction ≥ 55% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan.\n6. Disease that can be evaluated radiographically, which can be measurable disease or non-measurable disease per RECIST 1.1. All radiology studies must be performed within 28 days prior to start of study-directed therapy.\n7. Tumor that is amenable to fresh biopsy, which may include malignant ascites that is amenable for paracentesis.\n8. Baseline QTc interval \\\u003C 460 ms for females and ≤ 450 ms for males (average of triplicate readings) using Fredericia's QT correction formula. NOTE: This criterion does not apply to subjects with a right or left bundle branch block.\n9. Adequate recovery from toxicities related to prior treatments to at least Grade 1 by CTCAE v 5.0. Exceptions include alopecia and peripheral neuropathy grade ≤ 2. Subjects with other toxicities that are stable on supportive therapy may be allowed to participate with prior approval from the principal investigator.\n10. The effects of the study drugs on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (see Section 7.6 for Contraception Guidance) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after the last dose of the study drug.\n11. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Systemic anti-cancer therapy within 3 weeks of the first dose of study therapy, or within 5 half-lives of the previous drug, whichever is shorter.\n2. Patients currently receiving any other investigational agent.\n3. Subjects may not have had a history of malignancy other that esophagogastric cancer within two years prior to screening, with the exception of those with a negligible risk of metastasis or death (e.g., 5-year overall survival \\>90%) such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer.\n4. Major surgery within 4 weeks or palliative radiotherapy within 1 week of the first dose of study therapy.\n5. Treatment with warfarin. Subjects on warfarin for DVT\u002FPE can be converted to low- molecular-weight heparin (LMWH).\n6. History of treatment with a direct and specific inhibitor of FAK, MEK, or KRAS.\n7. Patients who had exposure to medications (with or without prescriptions), supplements, herbal remedies, or foods with potential for drug-drug interactions with avutometinib and\u002For defactinib within 14 days prior to the first dose of study intervention and during the course of therapy, including:\n\n   1. Strong CYP3A4 inhibitors or inducers.\n   2. Strong CYP2C9 inhibitors or inducers.\n   3. Strong P-glycoprotein (P-gp) inhibitors or inducers\n   4. Strong breast cancer resistance protein (BCRP) inhibitors or inducers\n8. Symptomatic brain metastases requiring steroids or other local interventions. Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these metastases for at least 4 weeks prior to first dose of study therapy, and are neurologically stable.\n9. Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection that is active and\u002For requires therapy. HIV patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with the investigational agents.\n10. Active skin disorder that has required systemic therapy within the past 1 year.\n11. History of rhabdomyolysis.\n12. Concurrent ocular disorders including the following:\n\n    1. Patients with history of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes.\n    2. Patients with history of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure \\> 21 mm Hg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO.\n    3. Patients with active or chronic, visually significant corneal disorders, other active ocular conditions requiring ongoing therapy or clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy. Examples of visually significant corneal disorders include corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions. Visually significant corneal disorders do NOT include dry eyes, blepharitis, and uncomplicated corneal erosions.\n13. Concurrent congestive heart failure, prior history of class III\u002FIV cardiac disease (New York Heart Association \\[NYHA\\]), myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina or severe obstructive pulmonary disease.\n14. Inability to swallow oral medications.\n15. History of hypersensitivity to any of the inactive ingredients (hydroxylpropylmethylcellulose, mannitol, magnesium stearate) of the investigational product.\n16. Female subjects who are pregnant or breastfeeding. Pregnant women are excluded from this study because the risk for teratogenic or abortifacient effects with the investigational agents is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated with the investigational agents.\n17. Any other medical condition (e.g., cardiac, gastrointestinal, pulmonary, psychiatric, neurological, genetic, etc.) that in the opinion of the investigator would place the subject at unacceptably high risk for toxicity.",{"count":558,"type":22},27,[255],"The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.",[152,29],"2025-10-31",{"date":564,"type":41},"2025-11-04",{"date":566,"type":41},"2024-10-28",{"date":568,"type":22},"2029-05-30",{"name":570,"class":48},"Ryan H. Moy, MD, PhD",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":49},"100531445","phase-2-clinical-efficacy-and-safety-of-paclitaxel-polymeric-micelles-for-injection-in-the-treatment-of-patients-with-taxans-resistant-pancreatic-adenocarcinoma-cholangiocarcinoma-lung-cancer-gastric-cancer-esophageal-carcinoma-or-breast-cancer-100531445","NCT06199895","Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer","Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxanes-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer","Inclusion Criteria:\n\n* 1.Male or female 18 years and older; 2.Patients with advanced pancreatic adenocarcinoma, cholangiocarcinoma, lung cancer, gastric cancer, esophageal carcinoma, or breast cancer diagnosed by histological or cytological pathology; must have an evaluable lesion; 3.Previous treatment regimen includes Taxanes and is resistant to Taxanes (including patients with initial failure to remit or progression after remission) or previous use of Taxanes for at least 2 cycles without tumour shrinkage and the patient is not satisfied with current stable efficacy and is willing to be enrolled in this study; 4.ECOG (Eastern Cooperative Oncology Group) score ≤ 2 points; 5.expected survival of at least 3 months; 6.Blood routine examination meets the following criteria:\n\n  1. WBC≥3.0×109 \u002FL，ANC≥1.5×109 \u002FL;\n  2. PLT≥100×109 \u002FL；\n  3. Hb≥80g\u002FL； 7.Blood biochemical examination must meet the following criteria:\n\n  \u003C!-- -->\n\n  1. Total bilirubin ≤1.5 times the upper limit of normal (ULN)；\n  2. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) ≤2.5 times ULN (ALT, AST, or ALP≤ 5×ULN for subjects with liver metastases, and ALP≤10×ULN for subjects with bone metastases);\n  3. Creatinine clearance (calculated using Cockcroft-Gault formula) ≥50 ml\u002Fmin； 8.Functions of major organs such as heart, lung, liver and kidney are basically normal； 9.Subjects have good compliance and voluntarily comply with the clinical trial protocol during the study, followed up by the investigators； 10.All women of childbearing age, men of childbearing potential, or their spouses who have no plans to have children or donate sperm during the entire trial period and up to 6 months after the last dose of medication, or who voluntarily used effective contraception; Women of childbearing age who have a negative blood\u002Furine pregnancy test within 7 days prior to enrollment； 11.Subjects had fully understood the study and voluntarily signed the informed consent form .\n\nExclusion Criteria:\n\n* 1.Subjects with an allergic history to experimental drugs or any excipients； 2.Subjects with acute or chronic infections that have not been eliminated, or subjects with other serious diseases at the same time; 3.Subjects with active hepatitis and uncontrolled by antiviral therapy, or liver metastasis is more than 3\u002F4 of the whole liver； 4.Subjects with third-space effusions (e.g., moderate-to-massive pleural effusion, moderate-to-massive pericardial effusion, ascites) that cannot be controlled by drainage or other means; 5.Subjects with mental illness or disorder, poor compliance, or inability to cooperate, or describe treatment responses； 6.Subjects who cannot tolerate chemotherapy due to severe organic disease or major organ failure, such as decompensated heart and lung failure； 7.Subjects with bleeding disorders； 8.Subjects with organ transplant; 9.Subjects with bad drug addicts, long-term alcoholics, infectious diseases such as AIDS； 10.Subjects who still have grade ≥2 toxicity from previous antineoplastic therapy (except alopecia and grade ≤2 neurotoxicity caused by platinum) at enrollment; 11.Subjects are considered not able to complete the trial or otherwise unfit to participate in the study by the investigators.",{"count":7,"type":22},[255],"This study is a single-center, single-arm, open-label, phase II clinical trial designed to evaluate the efficacy and safety of Paclitaxel Polymeric Micelles for Injection for the treatment of patients with advanced pancreatic adenocarcinoma, cholangiocarcinoma, lung cancer, gastric cancer, esophageal carcinoma, or breast cancer that are resistant to Taxanes.\n\nSubjects are given paclitaxel polymeric micelles for injection, three weeks constitutes one cycle of treatment.\n\nIf subject does not develop disease progression , the subject continues treatment until disease progression (RECIST 1.1) or develops an intolerable toxicity, initiation of a new anti-cancer drug, withdrawal from the study, death, or loss of follow-up.\n\nThis is a single-arm, small-sample clinical study with the primary efficacy goal of objective remission rate (ORR). The parameters of the trial were set: assuming a class I error of 0.025 unilaterally, power=90%, and a 15% improvement in ORR for objective remission rate, a total of 20 subjects would be required, and a total of 25 would be required for enrolment, taking into account a 20% shedding.",[582,583,120,29,584,66],"Pancreatic Adenocarcinoma","Cholangiocarcinoma","Esophageal Carcinoma","2025-05-31",{"date":587,"type":41},"2025-06-03",{"date":589,"type":41},"2023-11-28",{"date":591,"type":22},"2025-11",{"name":593,"class":48},"Liu Huang",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":19,"enrollmentInfo":602,"targetDuration":4,"studyType":23,"phases":604,"briefSummary":606,"conditions":607,"keywords":621,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":189},"100518299","phase-2-total-neoadjuvant-flot-chemotherapy-in-locally-advanced-gastric-and-gastroesophageal-junction-cancer-100518299","NCT06028737","Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin, and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Multi-center, Open-label Trial, Phase 2\u002F3","OCTASUR","Inclusion Criteria:\n\n* Tumor spread according to TNM: ≥cT3 and\u002For ≥cN0 and M0 (except of invasion of the common hepatic artery, celiac trunk, proximal part of the splenic artery, aorta, head of the pancreas);\n* Performance status by Eastern Cooperative Oncology Group (ECOG): 0 - 1;\n* Histologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert type 2\u002F3) adenocarcinoma.\n* Differentiation grade: G0 - G4;\n* Tumor localization: cardio-esophageal junction (Siewert 2, 3), cardiac part of the stomach, body of the stomach, antral part of the stomach, pyloric part of the stomach;\n* Tumor extension: esophagus, diaphragm, liver, body and tail of the pancreas, anterior abdominal wall, small and large intestine, distal part of the splenic artery, spleen;\n* Patient agrees to participate in this biomedical study.\n\nExclusion Criteria:\n\n* Presence of another oncological disease at a different site if less than 5 years have passed since radical treatment.\n* Comorbidities or patient conditions that preclude the administration of chemotherapy.",{"count":603,"type":22},150,[255,605],"PHASE3","The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles of chemotherapy and radical surgical treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery:\n\n1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, and Docetaxel (FLOT) followed by surgery.\n2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.",[152,29,608,609,610,611,612,613,90,614,615,616,617,618,619,620],"GastroEsophageal Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Adenocarcinoma","Gastric Neoplasm","Stomach Neoplasm","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Carcinoma","Chemotherapy","Gastrectomy","Gastrectomy for Gastric Cancer","Gastric Resection","Gastric (Cardia, Body) Cancer",[622,623,624,617,625,626,627,628,629],"Total neoadjuvant chemotherapy","FLOT","Fluoruracil","Perioperative chemotherapy","Docetaxel","Leucovorin","Gastric resection","Gastric cancer","2025-04-30",{"date":632,"type":41},"2025-05-06",{"date":634,"type":41},"2025-03-25",{"date":636,"type":22},"2032-12-31",{"name":638,"class":48},"Ukrainian Society of Clinical Oncology",{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":17,"minAge":647,"maxAge":457,"enrollmentInfo":648,"targetDuration":4,"studyType":23,"phases":650,"briefSummary":651,"conditions":652,"keywords":655,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":663,"completionDateStruct":665,"leadSponsor":667,"locationsCount":49},"100430829","comparison-of-endoscopic-resection-and-surgery-for-early-gastric-cancer-with-undifferentiated-histological-type-100430829","NCT04890171","Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type","Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type: a Multicenter Randomized Controlled Trial (ERASE-GC Trial)","ERASE-GC","Inclusion Criteria:\n\n1. Patients who are diagnosed with undifferentiated type EGC (signet ring cell carcinoma, poorly differentiated tubular adenocarcinoma, or poorly cohesive carcinoma) that meets the expanded indication of ESD 1) Tumor confined to the mucosa without ulcer, and size ≤2 cm on endoscopic evaluations 2) No evidence of lymph node metastasis and distant metastasis on abdominal CT scan\n2. Adult patients aged 19-75 years\n3. Patients who had willingness to sign an informed consent form\n\nExclusion Criteria:\n\n1. Patient age: \\\u003C 19 years or age \\> 75 years\n2. Diagnosis and active treatment for other organ cancer except carcinoma in situ and non-melanomatous skin cancer within 5 years\n3. Previous gastrectomy or esophagectomy history\n4. Multiple gastric cancers\n5. Current treatment for serious medical condition which could hinder study participation including severe heart dysfunction, liver cirrhosis, renal failure, chronic obstructive pulmonary disease or asthma, or uncontrolled infection\n6. Inability to provide an informed consent\n7. Inadequate conditions for study enrollment according to the evaluation of study physicians","19 Years",{"count":649,"type":22},708,[25],"This multi-center, randomized controlled trial is designed to evaluate clinical effectiveness and cost-effectiveness of ESD for undifferentiated type of EGC meeting the expanded indication compared with surgery.",[29,653,654],"Undifferentiated Type","Expanded Indication of Endoscopic Resection",[656,657,28,658,659],"Early gastric cancer","Endoscopic submucosal dissection","Undifferentiated type","Expanded indication","2024-12-25",{"date":662,"type":41},"2024-12-27",{"date":664,"type":41},"2021-06-11",{"date":666,"type":22},"2029-02-28",{"name":668,"class":669},"National Cancer Center, Korea","OTHER_GOV",{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":676,"eligibilityCriteria":677,"healthyVolunteers":12,"sex":17,"minAge":678,"maxAge":679,"enrollmentInfo":680,"targetDuration":4,"studyType":23,"phases":682,"briefSummary":683,"conditions":684,"keywords":689,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":697,"lastUpdatePostDateStruct":698,"startDateStruct":700,"completionDateStruct":702,"leadSponsor":704,"locationsCount":49},"100557029","phase-1-til-therapy-combined-with-pembrolizumab-for-advanced-or-metastatic-refractory-stomach-and-esophageal-cancer-100557029","NCT06532799","TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer","Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab (Keytruda) Immunotherapy in Patients With Advanced or Metastatic Refractory Stomach and Esophageal Cancer","BAH250","Inclusion Criteria:\n\n* Age: 16 years to 90 years\n* Histologically diagnosed as primary\u002Frelapsed\u002Fmetastasized Cancer\n* Expected life span more than 3 months\n* Karnofsky≥60% or ECOG score 0-2\n* Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.\n* Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated\n* At least 1 evaluable tumor lesion\n* Hematology and Chemistry（within 7 days prior to enrollment）:\n* Absolute count of white blood cells≥2.5×10\\^9\u002FL\n* Absolute count of neutropils≥1.5×10\\^9\u002FL\n* Absolute count of lymphocytes ≥0.7×109\u002FL\n* Platelet count≥100×10\\^9\n* hemoglobin≥90 g\u002FL\n* Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days)\n* Serum creatinine ≤1.5mg\u002FdL(or ≤132.6μmol\u002FL), or clearance rate≥50mL\u002Fmin\n* Serum ALT\u002FAST ≤3×ULN(subjects with liver metastasis ≤3×ULN)\n* Totol bilirubin≤1.5×ULN\n* No absolute or relative contraindications to operation or biopsy\n* Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent and continue within 1 year after the completion of lymphodepletion\n* Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy, and biologics must cease 28 days before obtaining TILs\n* Be able to understand and sign the informed consent document;\n* Be able to stick to the follow-up visit plan and other requirements in the agreement.\n\nExclusion Criteria:\n\n* Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment\n* Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%\n* Significant cardiovascular anomalies according to any of the following definitions:\n* New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant\n* Low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrioventricular conductive block, etc.\n* Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and\u002For anti-HCV positive), syphilis infection or Treponema pallidum antibody positive.\n* Severe physical or mental diseases;\n* Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection).\n* Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy.\n* History of allergy to chemical compounds consisting of chemical and biological substances resembling cell therapy.\n* Having received immunotherapy and developed an irAE level greater than Level 3.\n* Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded).\n* Females in pregnancy or lactation. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy.\n* Researchers consider the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.","16 Years","90 Years",{"count":681,"type":22},75,[61,255],"This Phase I\u002FII study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory stomach and esophageal cancer. Lifileucel (Amtagvi), the first FDA-approved TIL therapy, has shown significant promise in treating unresectable or metastatic melanoma by leveraging the patient's own immune cells to target and destroy cancer cells. This study aims to apply a similar approach to stomach and esophageal cancers. TILs will be harvested from patients' tumors, expanded in vitro, and infused back into the patients following a non-myeloablative lymphodepletion regimen. Pembrolizumab, a monoclonal antibody that targets the PD-1 receptor on T cells, will be administered to enhance the immune response. The primary endpoint is to determine the objective response rate (ORR) of this combined therapy. Secondary endpoints include disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This trial aims to provide a novel, personalized treatment option for patients with limited therapeutic alternatives.",[29,312,685,67,686,687,688],"Stomach Cancer, Adenocarcinoma","Esophageal Cancer Metastatic to Bone","Esophageal Cancer Metastatic to Lung","Esophageal Cancer Metastatic to Liver",[690,691,692,693,263,694,695,696],"CAR-T Cell Therapy","CAR-T","Tumor Infiltrating Lymphocytes","Advanced or Metastatic Refractory","TIL","Biological Therapy","Pembrolizumab","2024-11-10",{"date":699,"type":41},"2024-11-12",{"date":701,"type":41},"2024-09-10",{"date":703,"type":22},"2026-12-28",{"name":705,"class":48},"Essen Biotech",{"id":707,"slug":708,"hasResults":12,"nctId":709,"briefTitle":710,"officialTitle":710,"acronym":4,"eligibilityCriteria":711,"healthyVolunteers":197,"sex":17,"minAge":57,"maxAge":457,"enrollmentInfo":712,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":714,"conditions":715,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":722,"lastUpdatePostDateStruct":723,"startDateStruct":725,"completionDateStruct":727,"leadSponsor":729,"locationsCount":49},"100566307","development-and-demonstration-of-intelligent-assessment-based-on-multi-modal-information-fusion-for-tumor-risk-and-diagnosis-and-treatment-100566307","NCT06653478","Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment","Inclusion Criteria:\n\n1. Participants with the suspected of lung cancer\u002Fnode, or stomach cancer\u002Flesion, or colorectal cancer\u002Fleision\n2. Participants that have signed informed consent.\n3. Participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information.\n4. Healthy participants with no clinical diagnosis of lung cancer\u002Fnode, or stomach cancer\u002Flesion, or colorectal cancer\u002Fleision.\n\nExclusion Criteria:\n\n1. Participants with primary clinical and pathological data missing.\n2. Participants lost to follow-up.\n3. Participants with too poor medical image quality to perform segment and mark ROI accurately",{"count":713,"type":22},3000,"To improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features, pathological features, and multi-omics information and to develop a multi-modal data fusion-based technology system using artificial intelligence technology based on database.",[716,717,120,718,29,91,719,720,721],"Artificial Intelligence","Deep Learning","Lung; Node","Cancer Risk","Cancer Screening","Cancer, Treatment-Related","2024-10-20",{"date":724,"type":41},"2024-10-22",{"date":726,"type":41},"2022-06-01",{"date":728,"type":22},"2026-10-01",{"name":730,"class":48},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":732,"slug":733,"hasResults":12,"nctId":734,"briefTitle":735,"officialTitle":736,"acronym":4,"eligibilityCriteria":737,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":738,"targetDuration":4,"studyType":23,"phases":740,"briefSummary":741,"conditions":742,"keywords":743,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":744,"lastUpdatePostDateStruct":745,"startDateStruct":747,"completionDateStruct":749,"leadSponsor":751,"locationsCount":49},"100472092","phase-2-kn026-in-combination-with-chemotherapy-in-her2-positive-gastric-cancer-subjects-who-have-failed-first-line-therapy-100472092","NCT05427383","KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","A Randomized, Multicenter, Phase Ⅱ\u002FШ Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Histologically or cytology-confirmed HER2-positive locally advanced, recurrent, or metastatic gastric cancer (including adenocarcinoma of the gastro-esophageal junction); HER2 positive is defined as IHC 3+, or IHC 2+ with ISH test positive (HER2\u002FCEP17 ratio ≥ 2.0, or mean HER2 copy number ≥ 6.0 signals\u002Fcell);\n3. Failure of at least first-line standard therapy (trastuzumab plus chemotherapy); Note: Neoadjuvant\u002Fadjuvant therapy previously administered with a trastuzumab-containing regimen can be considered first-line therapy if the subject has progressed disease during neoadjuvant\u002Fadjuvant therapy or within 6 months of completion of treatment;\n4. Stage 1 : At least one measurable lesion at baseline according to RECIST 1.1; Stage 2: At least one evaluable lesion at baseline according to RECIST 1.1; the area must not have received previous radiotherapy, or there must be evidence of significant progression after the end of radiotherapy;\n5. ECOG Performance Status of 0 to 1.\n6. Life expectancy ≥ 3 months.\n7. 7\\. The function of major organs must meet the following criteria : Hemoglobin (Hb) ≥ 90 g\u002FL; Absolute neutrophil (ANC) ≥ 1.5×10\\^9\u002FL; Platelet (PLT) ≥ 90×10\\^9\u002FL; (No whole blood or component blood transfusion in the last 14 days; no pro-hematopoietic cytokines used in the last 7 days); AST, ALT ≤2.5× ULN (upper limit of normal value) (if liver metastases, AST, ALT ≤5×ULN); Total bilirubin (TBIL) ≤1.5×ULN; Albumin≥ 28 g\u002FL; creatinine clearance ≥ 50 mL\u002Fmin (standard Cockcroft-Gault formula applied); Activated partial thromboplastin time (APTT) ≤ 1.5×ULN, international normalized ratio (INR)\u002For prothrombin time (PT) ≤ 1.5×ULN; (It is allowed to receive anticoagulants at low stable doses, eg at a dose of aspirin 100 mg\u002Fday);\n8. Left ventricular ejection fraction (LVEF) ≥ 50% or lower limit of normal (LLN) in local sites, measured by echocardiography (ECHO), cardiac radionuclide scanning (MUGA) only in the absence of ECHO, with consistency at baseline and follow-up measurements;\n9. Subjects agreed to use effective contraception during the study and for 6 months after the last dose (women of childbearing age must confirm a negative serum pregnancy test within 7 days prior to enrollment);\n10. Female and male patient of childbearing age must agree to take adequate contraceptive measures during the entire study period and through at least 6 months after the last dose of study drug. (Women of childbearing age must have a negative pregnancy test prior to study entry.)\n11. Subjects are able and willing to comply with the study protocol.\n\nExclusion Criteria:\n\n1. Subjects with untreated active brain metastases; Subjects will be admitted if their brain metastases have been treated and the metastases are stable (brain imaging at least 4 weeks prior to the first dose showed stable lesions with no new CNS symptoms, or CNS symptoms have returned to baseline and no hormonal therapy is required at least 14 days prior to the first dose of the investigational treatment), and there is no evidence of new or enlarged original brain metastases;\n2. Other investigational medications received within 4 weeks prior to the first study treatment, based on the time of the last trial dose;\n3. Antineoplastic therapy such as chemotherapy, small molecule inhibitors, immunotherapy (such as interleukin, interferon, or thymosin) within 4 weeks or 5 half-lives (whichever is shorter but at least 2 weeks) prior to the first study treatment; Have received Chinese herbal treatment with antitumor activity within 14 days before administration;\n4. Subjects recieved major surgery (e.g., transabdominal, transthoracic, etc.) within 28 days prior to the first study treatment; does not include minor procedures such as diagnostic puncture or infusion device implantation), or major surgery is expected to be required during the study;\n5. Previous cumulative doses of doxorubicin exceeding 320 mg\u002Fm\\^2, or equivalent conversion of other anthracyclines (anthracycline equivalent: 1 mg doxorubicin = 2 mg epirubicin = 2 mg pyrrubicin = 2 mg daunorubicin = 0.5 mg normethoxydaunorubicin = 0.45 mg mitoxantrone; except doxorubicin liposomes);\n6. Previous use of anti-HER2 therapy other than trastuzumab (eg, ADC, dual-antibody, small molecule targeted therapy, etc.).\n7. Pregnant or lactating women; or intend pregnancy during the trial or within 6 months of the end of the trial;\n8. Subjects with a history of life-threatening allergies or known allergies to protein drugs or recombinant proteins or to one of excipients in KN026 drugs (histidine, glacial acetic acid, sucrose, and polysorbate 20) who have had a severe hypersensitivity reaction to trastuzumab.\n9. Adverse events have not returned to CTCAE 5.0 grade ≤ grade 1 or baseline from previous anti-tumor treatments , except for alopecia, skin pigmentation and those assessed by the investigators without potential safety risk.\n10. Uncontrollable diarrhoea (≥grade 2 that does not improve within 48 hours of medication);\n11. Subjects with the following history of cardiovascular disease:\n\n    * Subjects with uncontrolled hypertension (defined as sustained systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\> 100 mmHg despite antihypertensive medication);\n    * Any history of symptomatic congestive heart failure (NYHA classification II-IV); the absolute value of LVEF decreased by ≥10% and absolute value \\\u003C 50% , or the absolute value of LVEF decreased by ≥15% , during or after treatment with trastuzumab or other anti-HER2 treatment;\n    * History of myocardial infarction within 6 months before treatment of the first dose;\n    * Subjects with angina and unstable angina within three months prior to treatment in the first dose;\n    * Severe arrhythmias and conduction abnormalities requiring antiarrhythmic therapy other than β-blockers or digoxin (except atrial fibrillation and paroxysmal supraventricular tachycardia) within 6 months prior to treatment in the first dose;\n    * QTcF \\> 450 ms (male); QTcF \\> 470ms (Female);\n    * Other heart diseases that the investigators consider clinically significant;\n12. Poorly controlled systemic diseases judged by investigators, including diabetes;\n13. Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral therapy (eg, anti-infective drugs have been used for more than 1 week before the trial and will continue to be used), including tuberculosis infection;\n14. Received systemic corticosteroids (\\> 10 mg\u002Fday of prednisone, or equivalent amounts of other corticosteroids) within 2 weeks prior to treatment in the first dose; inhaled steroids or topical cortisol is permitted, corticosteroids are allowed for pre-treatment of certain chemotherapy drugs, and short-term (≤ 7 days) are allowed for the prevention or treatment of contrast allergy;\n15. History of noninfectious interstitial lung disease, or interstitial pneumonia requiring hormonal therapy;\n16. History of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency disease, or a history of organ transplantation;\n17. Active HBV \\[HBsAg or HBcAb-positive with HBV DNA \\> 500 IU\u002FmL (or 2500 copies\u002FmL)\\] or HCV infection \\[subjetcs with polymerase chain reaction (PCR)-negative HCV ribonucleic acid (RNA) can participate in this study\\] or HIV-positive or syphilis antibody positive (confirmed);\n18. History of any other malignant tumors within five years prior to the first dose, except cured cutaneous squamous cell carcinoma, basal cell carcinoma, non-muscle-invasive bladder cancer, localized low-risk prostate cancer \\[defined as stage ≤ T2a, Gleason score ≤ 6, and PSA ≤ 10 ng\u002FmL at prostate cancer diagnosis (if measured) who have received radical therapy and no biochemical recurrence of prostate-specific antigen (PSA) can participate in this study\\], cervical\u002Fbreast cancer in situ who have received radical treatment without any signs of recurrence and metastasis;\n19. Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) requiring drainage or diuretic therapy, within 2 weeks prior to the first dose of treatment; Diuretics for other reasons are permitted;\n20. Known mismatch repair deficient (dMMR) or highly unstable microsatellite (MSI-H) without previous PD-1\u002FPD-L1 monoclonal antibody therapy;\n21. Unintentional weight loss of ≥5% within 1 month prior to the first dose, despite peripheral or central venous nutritional support;\n22. Inability to tolerate or refuse chemotherapy required by the protocol;\n23. The investigator considered the subject to be unsuitable for participation in this clinical study due to the presence of any clinical or laboratory abnormalities or history of systemic disease or other reasons.",{"count":739,"type":22},286,[255,605],"KN026-001 is a two-stage study (Open-label stage\u002FRandomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together. Randomized stage is designed to evaluate the OS and PFS in patients receiving KN026 and chemotherapy compared to patients receiving placebo and chemotherapy.",[29],[613,152,610],"2023-12-11",{"date":746,"type":41},"2023-12-19",{"date":748,"type":41},"2022-04-07",{"date":750,"type":22},"2026-11",{"name":752,"class":78},"Shanghai JMT-Bio Inc.",{"id":754,"slug":755,"hasResults":12,"nctId":756,"briefTitle":757,"officialTitle":758,"acronym":759,"eligibilityCriteria":760,"healthyVolunteers":12,"sex":17,"minAge":57,"maxAge":457,"enrollmentInfo":761,"targetDuration":4,"studyType":23,"phases":763,"briefSummary":764,"conditions":765,"keywords":770,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":777,"lastUpdatePostDateStruct":778,"startDateStruct":780,"completionDateStruct":782,"leadSponsor":784,"locationsCount":49},"100477215","phase-2-xelox-combined-with-anlotinib-and-penpulimab-vs-xelox-as-adjuvant-therapy-in-ctdna-positive-gastric-and-esophagogastric-junction-adenocarcinoma-100477215","NCT05494060","XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma","XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma, a Randomized, Controlled, Multicenter Clinical Trial","EXPLORING","Inclusion Criteria:\n\n* Subjects aged ≥18 and ≤75 years old, male or female.\n* ECOG performance status score 0-1.\n* Histologically or cytologically confirmed GC or GEJ carcinoma, had been treated with Radical resection (D2, R0 or R1) of gastric cancer.\n* Pathological stage:III (8th AJCC TNM).\n* Estimated lifetime is greater than 6 months.\n* The main organs are functioning well, and the blood test results within 14 days before enrollment should meet the following requirements:\n\n  1. Routine blood test:\n\n     1. Hemoglobin (HB) ≥90 g\u002FL.\n     2. Neutrophil count (ANC) ≥1.5×109\u002FL.\n     3. Platelet count (PLT) ≥100×109\u002FL.\n  2. Biochemical test:\n\n     1. Total bilirubin≤1.5×ULN (upper limit of normal).\n     2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN; if there is liver metastasis, ALT and AST ≤ 5×ULN.\n     3. Serum creatinine (Cr) ≤1.5 ULN or creatinine clearance ≥60mL\u002Fmin.\n* No obvious clinical symptoms of heart disease.\n* Must have disease-free status documented by complete physical examination and imaging studies with no evidence of recurrent, residual, or metastatic disease on standard imaging (chest, abdomen, and pelvis captured by CT chest and CT or MRI of abdomen and pelvis) per investigator assessment within 28 days prior to enrollment.\n* Females of childbearing potential must have a negative urine or serum pregnancy test within 7 days of randomization and must be willing to use a highly effective method of birth control (Appendix 9) for the duration of the study, and ≥ 120 days after the last dose of penpulimab and 180 days after the last dose of chemotherapy.\n* Volunteer to participate in this study and sign an informed consent form.\n* Considering that NGS analysis may take up to 10 working days, patients could receive 1 cycle of XELOX chemotherapy after ctDNA sampling.\n\nExclusion Criteria:\n\n* Participation in other drug clinical trials within four weeks.\n* Multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction.\n* History of bleeding, any bleeding event with a severity grade of 3 or higher per CTCAE 5.0 within 4 weeks before screening.\n* Patients with known central nervous system metastasis or history of central nervous system metastasis prior to screening. For patients with clinically suspected central nervous system metastases, CT or MRI must be performed within 28 days before enrollment to rule out central nervous system metastases.\n* Patients with hypertension and uncontrolled by antihypertensive drugs alone (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg); Patients with a history of unstable angina pectoris; Patients newly diagnosed as angina pectoris within 3 months before screening or myocardial infarction events within 6 months before screening; Arrhythmias (including QTcF ≥ 450 ms in men, ≥ 470 ms in women requiring long-term use of antiarrhythmic drugs and New York Heart Association Class ≥ II cardiac insufficiency;There are many factors that affect oral drug absorption (such as inability to swallow, nausea and vomiting, upper gastrointestinal obstruction, abnormal physiological function, malabsorption syndrome, etc.), which may affect anlotinib hydrochloride absorbers.\n* Long-term unhealed wound or unhealed fracture.\n* Imaging findings show that the tumor has invaded around important blood vessels or the patient's tumor has a very high possibility of invading important blood vessels during treatment and causing fatal massive hemorrhage as judged by the investigator.\n* Patients with abnormal coagulation function and bleeding tendency (the following criteria must be met within 14 days before randomization: INR is within normal range without anticoagulants or has no clinically significant abnormality); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or their analogues; patients with prothrombin time international normalized ratio (INR) ≤ 1.5 are allowed to take low-dose warfarin (1 mg orally, once daily) or low-dose aspirin (the daily dose does not exceed 100 mg) for preventive purposes.\n* Arteriovenous thrombotic events occurred within 6 months before screening, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except venous thrombosis caused by previous chemotherapy that has been judged by the investigator to have recovered) and pulmonary embolism.\n* Urine routine showed urine protein and 24 h urine protein was confirmed to be \\> 1.0g.\n* Previous use of immune targeted therapy drugs.\n* History of immunodeficiency, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation.\n* Patients with infectious pneumonia, pneumonitis, interstitial pneumonia and other conditions requiring corticosteroids.\n* History of severe chronic autoimmune diseases, such as systemic lupus erythematosus; history of inflammatory bowel disease such as ulcerative enteritis, Crohn's disease, irritable bowel syndrome and other chronic diarrheal diseases; history of sarcoidosis or tuberculosis; history of active hepatitis B, C and HIV infection; well-controlled non-serious immune diseases, such as dermatitis, arthritis, psoriasis, etc. Hepatitis B virus \\\u003C 1000 copies\u002Fml can be detected.\n* Patients with hypersensitivity to human or murine monoclonal antibodies.\n* Patients with a history of psychotropic substance abuse and unable to quit or with mental disorders.\n* Pleural or peritoneal effusion with clinical symptoms requiring clinical intervention.\n* Patients who do not follow the doctor's advice, do not take medicine as required, or have insufficient data that can affect the efficacy judgment or safety judgment.\n* Patients with concomitant diseases that, in the judgment of the investigator, seriously jeopardize the patient's safety or affect the patient's completion of the study.",{"count":762,"type":22},80,[255],"This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma. The patients will be randomized into two arms consist of Penpulimab + Anlotinib (3 weeks\u002Fcycle) + XELOX and XELOX at a ratio of 1:1. This study is conducted to assess safety and anti-tumor activity of the monoclonal antibody Penpulimab in combination with Anlotinib and standard chemotherapy as adjuvant treatment for ctDNA-positive Gastric, or Gastroesophageal Junction Carcinoma.",[766,767,29,768,769,152,288],"Carcinoma","Gastrointestinal Diseases","Gastroesophageal-junction Cancer","Digestive System Diseases",[771,772,773,774,775,776],"Penpulimab","Anlotinib","Capecitabine","Oxaliplatin","ctDNA","adjuvant therapy","2023-11-03",{"date":779,"type":41},"2023-11-07",{"date":781,"type":41},"2022-03-16",{"date":783,"type":22},"2027-02",{"name":785,"class":48},"The First Affiliated Hospital with Nanjing Medical University"]